Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/468)
  • Patent number: 10426755
    Abstract: The present invention provides methods for treating cancer, by administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods for reducing cancer cell metastasis, by administering a therapeutically effective amount of a compound of formula (I) described herein or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: October 1, 2019
    Assignees: CHANG GUNG MEMORIAL HOSPITAL, CHIAYI, CHANG GUNG UNIVERSITY
    Inventors: Ching-Yuan Wu, Kuan-Der Lee, Hong-Yo Kang, Yu-Shih Lin
  • Patent number: 10287297
    Abstract: Disclosed is a compound of formula (I) in which R1-R5 and X1 are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer and a method of treating diabetes.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: May 14, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fundació Institut Català d'Investigació Quimica (ICIQ), Universitat Rovira i Virgili
    Inventors: John A. Beutler, Antonio M. Echavarren, Laura Lopez, Fernando Bravo, Lorena Riesgo, Tanya Tannaquil Ransom
  • Patent number: 10273220
    Abstract: A derivative of inula lineariifolia lactone A, and in particular, a dimethylamine 4-O-acetyl inula lineariifolia lactone A or a salt thereof, preparation of same, and an application of same in preparation of medicine for treating multiple sclerosis.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: April 30, 2019
    Assignee: Shanxi Zhendong Leading Biotechnology Co., Ltd.
    Inventors: Weidong Zhang, Qingyan Sun, Minghua Li, Baohua Yang
  • Patent number: 10220019
    Abstract: The present invention provides an application of a dimethylamino micheliolide for preparing a pharmaceutical product for treating pulmonary fibrosis.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: March 5, 2019
    Assignees: Tianjin International Joint Academy of Biotechnology & Medicine, ACCENDATECH
    Inventors: Tao Sun, Yue Chen, Cheng Yang, Honggang Zhou, Huijuan Liu, Yanrong Liu, Jing Wang, Chengyu Zhang, Qiang Zhang, Xiangming Zhang, Yuan Qin, Xueshuang Jing
  • Patent number: 10183925
    Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O) B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 22, 2019
    Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
  • Patent number: 10174072
    Abstract: In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: January 8, 2019
    Assignee: Ohio State Innovation Foundation
    Inventors: Abhay R. Satoskar, James F. Fuchs, Alan Douglas Kinghorn, Li Pan, Claudio M. Lezama-Davila, Eric Bachelder
  • Patent number: 10165778
    Abstract: A method for controlling pests of soybean plants comprises the step of contacting the soybean plant, parts of it, its propagation material, the pests, their food supply, habitat or breeding grounds with one or more components of the ginkgo tree selected from the group consisting of bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and ginkgolide M.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: January 1, 2019
    Assignee: BASF SE
    Inventors: Daniel Saelinger, Joachim Dickhaut, Karsten Koerber, Wolfgang von Deyn, Raffael Koller, Arun Narine, Jean-Yves Wach, Jochen Dietz
  • Patent number: 9895405
    Abstract: Present invention relates to a use of Radix Salviae Miltiorrhizae (Danshen) or its preparations in preparation of drugs for treating disease related to hepatic fibrosis.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: February 20, 2018
    Assignee: TASLY PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yonghong Zhu, Jinfang Hu, Jie Ma, Xiuping Shen
  • Patent number: 9877908
    Abstract: A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: January 30, 2018
    Assignee: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Patent number: 9801918
    Abstract: The present invention describes the use of pharmaceutical compositions including compounds of formula 2 (below) for treatment of infections related to M. tuberculosis and for anti-proliferative activity.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: October 31, 2017
    Assignee: Council of Scientific & Industrial Research
    Inventors: Swati Pramod Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
  • Patent number: 9801379
    Abstract: A method for controlling pests of soybean plants comprises the step of contacting the soybean plant, parts of it, its propagation material, the pests, their food supply, habitat or breeding grounds with one or more components of the ginkgo tree selected from the group consisting of bilobalide, ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and ginkgolide M.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: October 31, 2017
    Assignee: BASF SE
    Inventors: Daniel Saelinger, Joachim Dickhaut, Karsten Koerber, Wolfgang von Deyn, Raffael Koller, Arun Narine, Jean-Yves Wach, Jochen Dietz
  • Patent number: 9793491
    Abstract: The present disclosure relates to a compound represented by Formula 1 and an organic light-emitting device including the same. The compound represented by Formula 1 has excellent stability and is suitable as an electron transporting material. An organic light-emitting device using the compound of Formula 1 may have high efficiency, low voltage, high luminance, and long lifespan.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: October 17, 2017
    Assignee: Samsung Display Co., Ltd.
    Inventors: Seokhwan Hwang, Mieun Jun, Hyejin Jung, Youngkook Kim
  • Patent number: 9730472
    Abstract: A vaporization device and its method of use, where the device can accommodate a plurality of formulations for dispensing by selecting the desired source. Such formulations can include different drug formulations for providing different effects on the user. Also, an indicator with specialized indicia can be provided to identify the source being dispensed.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: August 15, 2017
    Inventor: Darrin B. Farrow
  • Patent number: 9682029
    Abstract: A ceramide production enhancer and a moisturizer containing, as an active ingredient, an extract of at least one plant selected from the group consisting of Chenopodium hybridum, Melia toosendan, Indigofera tinctoria, Cirsium japonicum, Catalpa ovata, and Tagetes erecta, or a compound represented by the following Formula (1): wherein, R represents an acyl group having 1 to 5 carbon atom(s).
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 20, 2017
    Assignee: Kao Corporation
    Inventors: Yoshie Shimotoyodome, Shotaro Ito, Yoshiya Sugai, Hiroshi Hashimoto, Junko Ishikawa
  • Patent number: 9445987
    Abstract: A ceramide production enhancer and a moisturizer containing, as an active ingredient, an extract of at least one plant selected from the group consisting of Chenopodium hybridum, Melia toosendan, Indigofera tinctoria, Cirsium japonicum, Catalpa ovate, and Tagetes erecta, or a compound represented by the following Formula (1): wherein, R represents an acyl group having 1 to 5 carbon atom(s).
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: September 20, 2016
    Assignee: Kao Corporation
    Inventors: Yoshie Shimotoyodome, Shotaro Ito, Yoshiya Sugai, Hiroshi Hashimoto, Junko Ishikawa
  • Patent number: 9403747
    Abstract: The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 2, 2016
    Assignee: Golden Biotechnology Corporation
    Inventors: Sheng-Yung Liu, Wu-Che Wen, Chih-Ming Chen
  • Patent number: 9278912
    Abstract: Disclosed herein are novel C13-hydroxy derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: September 10, 2013
    Date of Patent: March 8, 2016
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
  • Patent number: 9278086
    Abstract: The invention relates to compounds, methods, uses, compositions, combinations, kits and packages for the prevention and/or treatment of parasite infection (e.g., Plasmodium parasites) and/or disease (e.g., malaria) based on uses of (a) cystamine, cysteamine, and analogs, derivatives, prodrugs, precursors thereof; an agent capable of inducing their production; and/or salts thereof, and (b) artemisinin and functional derivative, analog, conjugate, metabolite, prodrug or precursor thereof, and/or salts thereof.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: March 8, 2016
    Assignee: The Royal Institution for the Advancement of Learning/McGill University
    Inventors: Philippe Gros, Gundula Min-Oo, Anny Fortin
  • Patent number: 9150530
    Abstract: The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: October 6, 2015
    Assignee: Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.
    Inventors: Zhiwei Jiang, Aijin Wang, Hongwei Hu, Jiali Xu, Yuesong Hu, Xian Li, Yan Ye, Jie Wang, Qinglong Li
  • Patent number: 9101601
    Abstract: Disclosed are methods of treating an animal for insulin resistance and associated diseases or conditions, activating the transcriptional activity of heat shock factor 1 (HSF1), or inducing the expression of heat shock protein 70 (HSP70) in an animal in need thereof, wherein the methods involve administering an effective amount of one or more compounds of formula (I) or an epimer thereof, wherein Ar, and R1-R6 are described herein. Examples of diseases or conditions associated with insulin resistance include diabetes, obesity, inflammation, metabolic syndrome, polycystic ovary disease, arteriosclerosis, non-alcoholic fatty liver disease, reproductive abnormality in a female, and growth abnormality.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: August 11, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Leonard M. Neckers, Carole A.C. Sourbier, W. Marston Linehan, Jane B. Neckers, Min-Jung Lee, Bradley T. Scroggins, John A. Beutler
  • Patent number: 9090549
    Abstract: 1,4 naphthoquinones derivatives, of formula (I) wherein A is selected from the following rings: their preparation and their application as antimalarial agents
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: July 28, 2015
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), REPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Elisabeth Davioud-Charvet, Tobias Muller, Holger Bauer, R. Heiner Schirmer
  • Patent number: 9090596
    Abstract: Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated pathologies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: July 28, 2015
    Assignee: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Branislav Musicki, Jerôme Aubert, Jean-Guy Boiteaux, Laurence Clary, Patricia Rossio, Marlène Schuppli-Nollet
  • Patent number: 9045450
    Abstract: The present invention provides a method for preparing antrocin of pharmaceutically acceptable salts thereof via a series of gold-catalyzed cyclization to construct the (6-6-5) tricyclic core frame. The present invention also provides a use of a composition in preparing drugs for suppressing growth of non-small cell lung cancer cells, wherein the composition comprises an effective amount of antrocin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: June 2, 2015
    Assignees: KAIYEW INVESTMENT CORP., JENISA BIOTECHNOLOGY CORP.
    Inventors: Zhen Yang, Yew-Min Tzeng, Chuang-Chuang Li, Tuo-Ping Luo, Hang Shi, Chi-Tai Yeh
  • Publication number: 20150148314
    Abstract: There are provided, inter alia, derivatives of seriniquinone and methods useful for the treatment of cancer, and in particular treatment of melanoma and prostate cancer.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: William Fenical, Paul R. Jensen, James J. La Clair, Lynnie Trzoss, Takashi Fukuda
  • Publication number: 20150148384
    Abstract: Disclosed herein are novel A-ring epoxidized triterpenoid compounds and derivatives thereof, including those of the formula (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 28, 2015
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Christopher F. Bender, Xin Jiang, Xiaofeng Liu, Haizhou Sun, Melean Visnick
  • Publication number: 20150141418
    Abstract: The present invention relates to methods, compounds, and compositions for inhibiting angiogenesis. More particularly, the present invention relates to methods, compounds, and compositions for inhibiting VEGF production.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 21, 2015
    Applicant: PTC Therapeutics, Inc.
    Inventors: William Lennox, Hongyan Qi, Duck-Hyung Lee, Soongyu Choi, Young-Choon Moon
  • Publication number: 20150142085
    Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: May 21, 2015
    Inventors: David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
  • Publication number: 20150134266
    Abstract: The present invention relates to a method of identifying the molecular basis of a drug compound's activity. The invention further relates to a pharmaceutical composition, a kit for treating psychosis in a subject, and a method for treating psychosis and/or schizophrenia.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: NEW YORK UNIVERSITY
    Inventors: Timothy J. CARDOZO, Evgeny V. SHMELKOV
  • Publication number: 20150133444
    Abstract: The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Venumadhav Janganati, Narsimha Reddy Penthala, Peter A. Crooks, Craig T. Jordan
  • Publication number: 20150126552
    Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-aminated methylene or 2-esterified methylene tanshinone I derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments. When X is nitrogen, formula I indicates 2-aminated methylene tanshinone I; when X is oxygen, formula I indicates 2-esterified methylene tanshinone I.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 7, 2015
    Applicant: Hangzhou Bensheng Pharmaceutical Co., Ltd.
    Inventors: Rongzhen Xu, Frank Rong, Fuwen Xie, Hongxi Lai
  • Publication number: 20150105457
    Abstract: Preparation and application of line leaf inula flower lactone A for treating myocarditis having a structure of The compound shows positive therapeutic activity against Coxsackie virus and significant dose dependent correlation. The line leaf inula flower lactone A prevents disease in mouse models of experimental autoimmune myocarditis and onset of the process by intraperitoneal injection of a dose of 20 mg/kg/d. When increased to 100 mg/kg/d, the line leaf inula flower lactone A shows positive therapeutic effect on EAM. Line leaf inula flower lactone A is used as the sole active ingredient and combined with a conventional pharmaceutical carrier in a drug for treating myocarditis, and the pharmaceutical composition may be in the form of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Weidong ZHANG, Lei SHAN, Huizi JIN, Juan SU, Huiliang LI, Yunheng SHEN, Xike XU, Runhui LIU
  • Publication number: 20150105458
    Abstract: Preparation and application of line leaf inula flower lactone A in the multiple sclerosis, having a structure of Line leaf inula flower lactone A has therapeutic effects on experimental autoimmune encephalomyelitis (EAE) model, and is used to develop drug for treating multiple sclerosis (MS). Line leaf inula flower lactone A drug is a combination containing the active ingredient of line leaf inula flower lactone A and conventional pharmaceutically carrier, and may be in forms of tablets, dispersible tablets, mouth collapse tablets, retard tablets, capsule, soft capsule, dropping pill, granules, injection, powder injection, or aerosol. The pharmaceutical composition is used for treating multiple sclerosis, has tremendous developing potentiality because of its high value of clinical application.
    Type: Application
    Filed: December 18, 2014
    Publication date: April 16, 2015
    Inventors: Weidong ZHANG, Lei SHAN, Juan SU, Huizi JIN, Huiliang LI, Yunheng SHEN, Xike XU, Runhui LIU
  • Publication number: 20150099731
    Abstract: The present invention provides compounds of the formula (I) wherein: X1, X2 and X3 are heteroatoms; R4, R5, R6, R7, R8, R9 and R10 are independently selected from H, halo, —OH, —NO2, —CN and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; and Z is optionally substituted C1-8 straight-chained or branched aliphatic, optionally containing 1 or more double or triple bonds, wherein one or more carbons are optionally replaced by R* wherein R* is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; an amino acid residue, H, —CN, —C(O)—, —C(O)C(O)—, —C(O)NR1—, —C(O)NR1NR2—, —C(O)O—, —OC(O)—, —NR1CO2—, —O—, —NR1C(O)NR2—, —OC(O)NR1—, —NR1NR2—, —NR1C(O)—, —S—, —SO—, —SO2—, —NR1—, —SO2NR1—, —NR1R2, or —NR1SO2—, wherein R1 and R2 are independently selected from H and optionally substituted aliphatic, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; or where R* is NR1R2, R1 and R2 optionally together with the nitrogen atom form an optionally substituted 5-12 me
    Type: Application
    Filed: May 5, 2014
    Publication date: April 9, 2015
    Applicant: University of Kentucky
    Inventors: Peter A. Crooks, Craig T. Jordan, Xiaochen Wei
  • Publication number: 20150093338
    Abstract: There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need thereof by inhalation of a composition containing amino acid ester compounds comprising at least one nitric oxide releasing group and pharmaceutical salts thereof.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 2, 2015
    Inventor: Michael Farber
  • Patent number: 8980944
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Gemmus Pharma Inc.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • Patent number: 8981131
    Abstract: The present invention provides compounds represented by formula I: wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-? and/or interleukins (IL-1?, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula 1 and pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: March 17, 2015
    Assignee: Piramal Enterprises Limited
    Inventors: Dilip Narayanrao Bhedi, Ram Asrey Vishwakarma, Vaishali Deka, Dattatray Maruti More, Manivannan Ramalingam, Ashish Suthar, Roda Dalal, Sapna Parikh, Aditi Amol Tannu
  • Publication number: 20150073030
    Abstract: The T cells specific to human collagen type II, one of the possible autoantigens, have a crucial role in the development of rheumatoid arthritis in the context of HLA-DR4. The protein-protein interactions between the T cell receptor (TCR) and the type II collagen linked to the allele MHC of class II HLA-DR4 may thus represent the target for the development of new drugs against rheumatoid arthritis. Using computational virtual screening techniques, families of pharmacologically active molecules have been identified that interfere with the TCR/collagen ll-MHCII interaction. The compounds identified here open up new possibilities in the treatment of rheumatoid arthritis.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Inventors: Maria Cristina De Rosa, Francesco Ria, Bruno Giardina, Gianfranco Ferraccioli, Davide Pirolli, Chiara Nicolo'
  • Patent number: 8975399
    Abstract: A benzene sulphonamide compound of formula I or one of its addition salts with pharmaceutically acceptable acids, for its use in a method for treating a pathology linked to an excessive effect of TNF-alpha and for its use in a method for treating the human or animal body as a direct inhibitor of TNF-alpha.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: March 10, 2015
    Inventors: Jean-Francois Zagury, Matthieu Montes, Hadley Mouhsine, Helene Guillemain
  • Publication number: 20150064168
    Abstract: Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.
    Type: Application
    Filed: July 3, 2014
    Publication date: March 5, 2015
    Inventors: Stephen W. Byers, Sivanesan Dakshanamurthy, Jaime M. Guidry Auvil, Milton L. Brown
  • Publication number: 20150065554
    Abstract: Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a modulator of a target related to neurofibromatosis. Also disclosed are screening assays involving the implementation of Merlin-null Schwann cells, and to compounds identified using same.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 5, 2015
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventor: Cristina Fernandez-Valle
  • Patent number: 8969409
    Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: March 3, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Martine A. Rothblatt, Lewis J. Rubin
  • Patent number: 8969410
    Abstract: A pharmaceutical composition for alleviating or treating gout and the applications thereof are provided. The pharmaceutical composition includes p-coumaryl diacetate as an active ingredient.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 3, 2015
    Assignee: Industrial Technology Research Institute
    Inventors: Ying-Chu Shih, Jenn-Line Sheu, Cheng-Yu Lee, Jir-Mehng Lo, Yi-Ching Lee, Ying-Fei Tsai, Yi-Cheng Cheng
  • Publication number: 20150057342
    Abstract: Provided are oral pharmaceutical compositions comprising sustained release or a combination of sustained and immediate release formulation of cannabinoids, a process for their preparation and methods of use thereof.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 26, 2015
    Inventors: Zohar KOREN, Eyal BALLAN, Itamar BOROCHOV, Shay Avraham SARID
  • Patent number: 8962575
    Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: February 24, 2015
    Assignee: Biotropics Malaysia Berhad
    Inventors: Matthias Gehling, Torsten Grothe, Ernst Roemer, Peter Reinemer, Kathrin Reinhardt, Annie George, Nur Hanisah Mohtar, Noorsyarida Mohd Sapiai
  • Publication number: 20150051277
    Abstract: The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to M. tuberculosis. The invention further discloses use of compound of formula 3 for the conversion of solar energy into electric current in dye sensitized solar cells.
    Type: Application
    Filed: August 6, 2012
    Publication date: February 19, 2015
    Inventors: Swati Pramod Joshi, Roshan Rajan Kulkarni, Ketaki Dilip Shurpali, Sampa Sarkar, Dhiman Sarkar
  • Publication number: 20150031725
    Abstract: Provided herein, inter alia, are compositions and methods useful for treating hyperproliferative diseases, including cancer and non-malignant hyperproliferative diseases.
    Type: Application
    Filed: October 2, 2014
    Publication date: January 29, 2015
    Inventors: Richard J. Pietras, Michael E. Jung, Diana C. Marquez-Garban, Gang Deng
  • Publication number: 20150025061
    Abstract: The present invention is directed to a method of enhancing visual acuity in a subject, comprising intravitreally administering to the subject in need of such enhancement, a therapeutically effective amount of an extrasynaptic GABAA receptor antagonist. The present invention is also directed to an ocular implant comprising a therapeutically effective amount of the extrasynaptic GABAA receptor antagonist.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 22, 2015
    Inventor: Movses H. Karakossian
  • Publication number: 20150018410
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: September 29, 2014
    Publication date: January 15, 2015
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Publication number: 20150011622
    Abstract: The present invention relates to an improved dosage form containing, as active ingredients, epitulipinolide and costunolide extracted from the bark of Liriodendron tulipifera and, more specifically, to a dosage form for treating the gastrointestinal tract, the dosage form containing, as active ingredients, epitulipinolide and costunolide, which are the active ingredients of the extract from the bark of Liriodendron tulipifera.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 8, 2015
    Applicant: CHO DANG PHARM. CO., Ltd.
    Inventor: Nak Doo Kim